Objective To investigate the clinical characteristics, bacterial spectrum, drug resistance rate and outcome of peritoneal dialysis-associated peritonitis (PDAP) by multiple drug resistant organisms (MDRO), so as to provide clinical evidences for standardizing therapy of PDAP by MDRO. Methods Clinical data of PDAP patients admitted to The Third Hospital of Hebei Medical University during January, 2016 and December, 2022 were retrospectively reviewed. They were divided into two groups based on the results of bacterial culture in effluent dialysate, PDAP by MDRO group and PDAP not by MDRO group. Clinical data and treatment results were compared between the two groups. Results ①In the 96 PDAP patients, a total of 123 PDAP episodes occurred, of which 56 episodes were PDAP by MDRO. The MDRO were dominated by Gram positive bacteria (49/56, 87.5%), in which the most strains were coagulase-negative staphylococci (41/49, 83.7%); all Gram negative bacteria were Escherichia coli (E. coli). ②The average time for significant improvement of PDAP was longer in PDAP by MDRO group than in PDAP not by MDRO group (Z=-1.994 and -2.341; P=0.046 and 0.019); the average time for significant improvement of PDAP caused by Gram positive bacteria was 2.491 days longer in PDAP by MDRO group than in PDAP not by MDRO group (t=-2.254, P=0.028). ③The sensitivity of Gram positive bacteria to rifampicin increased in 2020～2022 compared to that in 2016-2019 (χ2=4.416, P=0.042). ④In the PDAP caused by Gram positive bacteria, the recurrence rate of PDAP was higher in PDAP by MDRO group than in PDAP not by MDRO group (P=0.020). Conclusion The main pathogens in PDAP by MDRO group were coagulase-negative staphylococci. In PDAP patients by MDRO, the recurrence rate of PDAP was higher, the presence of PDAP symptoms was longer, and effective antibiotic therapy should be used earlier and longer.
[1]Tian Y, Xie X, Xiang S, et al. Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: a retrospective study[J]. Medicine, 2016, 95(49): e5569.
[2]Li P K-T, Chow K M, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2022, 42(2): 110-153.
[3] 李春辉, 吴安华. MDR、XDR、PDR多重耐药菌暂行标准定义——国际专家建议[J]. 中国感染控制杂志. 2014, 13(1): 62-64.
[4] Magiorakos A-P, Srinivasan A, Carey R B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance[J]. Clinical Microbiology and Infection, 2012, 18(3): 268-281.
[5] 中国腹膜透析相关感染防治专家组. 腹膜透析相关感染的防治指南[J].中华肾脏病杂志. 2018, 34((2): 139-148.
[6] Yang L, Gong N, Zhou H, et al. The pathogen spectrum and resistance in patients with peritoneal dialysis-associated peritonitis: a single-center, observational clinical study[J]. Clinical Nephrology, 2019, 92(1): 44-51.
[7] 许戎, 胡宁, 阿荣其其格. 腹膜透析相关性腹膜炎单中心8年变化趋势回顾分析[J]. 中国血液净化. 2013, 12(1): 37-41.
[8] Ozisik L, Ozdemir F N, Tanriover M D. The changing trends of peritoneal dialysis related peritonitis and novel risk factors[J]. Renal Failure, 2015, 37(6): 1027-1032.
[9] Flanigan M J, Lim V S. Initial treatment of dialysis associated peritonitis: a controlled trial of vancomycin versus cefazolin[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 1991, 11(1): 31-37.
[10] Chen H-C, Shieh C-C, Sung J-M. Increasing staphylococcus species resistance in peritoneal dialysis-related peritonitis over a 10-year period in a single taiwanese center[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2018, 38(4): 266-270.
[11] Ciofu O, Moser C, Jensen P ?, et al. Tolerance and resistance of microbial biofilms[J]. Nature Reviews Microbiology, 2022, 20(10): 621-635.
[12] Camargo C H, Da Cunha M De L R De S, Caramori J C T, et al. Peritoneal dialysis–related peritonitis due to coagulase-negative staphylococcus?: a review of 115 cases in a brazilian center[J]. Clinical Journal of the American Society of Nephrology, 2014, 9(6): 1074-1081.
[13] Aaron S D, Ferris W, Ramotar K, et al. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis[J]. Journal of Clinical Microbiology, 2002, 40(11): 4172-4179.
[14] Girard L P, Ceri H, Gibb A P, et al. MIC versus mbec to determine the antibiotic sensitivity of staphylococcus aureus in peritoneal dialysis peritonitis[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2010, 30(6): 652-656.
[15] Seni J, Sweya E, Mabewa A, et al. Comparison of antimicrobial resistance patterns of esbl and non esbl bacterial isolates among patients with secondary peritonitis at bugando medical centre, mwanza - tanzania[J]. BMC Emergency Medicine, 2016, 16(1): 41.
[16] Yip T, Tse K-C, Lam M-F, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing e. coli peritonitis in capd patients[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2006, 26(2): 191-197.
[17] Prasad K N, Singh K, Rizwan A, et al. Microbiology and outcomes of peritonitis in northern india[J]. Peritoneal Dialysis International, 2014, 34(2): 188-194.
[18] Feng X, Yang X, Yi C, et al. Escherichia coli peritonitis in peritoneal dialysis: the prevalence, antibiotic resistance and clinical outcomes in a south china dialysis center[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2014, 34(3): 308-316.
[19] 侯巍, 李实, 刘书中. 降钙素原临床应用进展[J]. 中国实验诊断学. 2014, 18(5): 870-871.
[20] Guz G, Colak B, Hizel K, et al. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2006, 26(2): 240-248.
[21] Lam M F, Leung J C K, Lam C W K, et al. Procalcitonin fails to differentiate inflammatory status or predict long-term outcomes in peritoneal dialysis-associated peritonitis[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2008, 28(4): 377-384.
[22] 张淑瑛, 冯敏亚, 王晓慧. 病原菌耐药程度与降钙素原检测结果的分析[J]. 国际检验医学杂志. 2020, 41(7): 886-888.
[23] Sia C S B, Paul E, Tregaskis P, et al. The longitudinal effects of peritonitis on peritoneal membrane function[J]. Clinical Nephrology, 2017, 88(12): 311-316. DOI: 10.5414/CN109071.
[24] 乔雨萌, 徐潇, 董捷. 腹膜透析相关性腹膜炎痊愈后全身系统性及局部炎症对临床预后的影响[J]. 中华肾脏病杂志. 2022, 38(6): 567-571.
[25] Htay H, Cho Y, Pascoe E M, et al. Center effects and peritoneal dialysis peritonitis outcomes: analysis of a national registry[J]. American Journal of Kidney Diseases, 2018, 71(6): 814-821.
[26] Wong S S Y, Ho P-L, Yuen K-Y. Evolution of antibiotic resistance mechanisms and their relevance to dialysis-related infections[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2007, 27(2_suppl): 272-280.
[27] 佟怡婧, 严豪, 李振元, 等. 711例腹膜透析相关性腹膜炎的致病菌谱变化及药物敏感分析[J]. 中华肾脏病杂志. 2017, 33(8): 601-608.
[28] Kitterer D, Latus J, P?hlmann C, et al. Microbiological surveillance of peritoneal dialysis associated peritonitis: antimicrobial susceptibility profiles of a referral center in germany over 32 years[J]. PLOS ONE, 2015, 10(9): e0135969.
[29] Zeng Y, Jiang L, Lu Y, et al. Peritoneal dialysis-related peritonitis caused by gram-negative organisms: ten-years experience in a single center[J]. Renal Failure, 2021, 43(1): 993-1003.
[30] Cho Y, Struijk D G. Peritoneal dialysis–related peritonitis: atypical and resistant organisms[J]. Seminars in Nephrology, 2017, 37(1): 66-76.
[31] Szeto C-C, Chow K-M, Kwan B C-H, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases[J]. Clinical Journal of the American Society of Nephrology, 2007, 2(2): 245-251.
[32] For The CIPPER Trial Group, De Fijter C W H, Ter Wee P M, et al. Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (c)apd-related peritonitis: a prospective randomized multicenter comparison (cipper trial)[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2001, 21(5): 480-486.
[33] Demoulin N, Goffin E. Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2009, 29(5): 548-553.
[34] 彭卫生, 周巧玲, 敖翔, 等. 腹膜透析相关性腹膜炎的细菌谱及耐药性分析[J]. 中南大学学报（医学版）, 2012, 37(12): 1205-1209.
